Authors:
G.-Y. Jin, Y. C. Lee, Y. H. Choi, Y. M. Han; Jeon-ju/KP
DOI:
10.1594/ecr2008/C-253
Results
The characteristics of sixty-five patients with lung malignancies are described in Table 1. We performed sixty-seven sessions of RFA and nine sessions of PTC. The mean follow-up period was 20.5 months (range 2.6-74.3 months; Median 20.8±4.7 months).
- Complete and partial ablation in pulmonary tumors by PTC or RFA
Of all session of procedure, complete ablation was attained in twenty-nine patients (43.3%) treated with RFA and six patients (66.7%) treated with PTC. The rate of complete ablation by RFA was 76.2% for tumors smaller than 3.0 cm (fig 1-3). In PTC group, 6 of 7 tumors smaller than 3.0 cm (85.7%) were ablated completely (fig 4).
During observed period, forty-two (64.6%) patients expired. The overall median survival duration was 20.8±4.7 months with that 1, 2, and 3-year survival rate of all patients were 67%, 46%, and 27%, respectively. Median survival durations of patients with complete ablation and with partial ablation were 34.6±6.8 months and 14.4±2.3 months (p=0.002), respectively. Kaplan-Meier analysis revealed that 1, 2, and 3-year survival rate were 79%, 62%, and 47%, respectively, in patients with complete ablation, and 57%, 32%, 9% in patients with partial ablation (fig 5). In the multivariate Cox regression model, we have found that the extent of ablation (i.e. complete ablation versus partial ablation) was closely related to all causes of mortality (HR=0.38, p<0.05).
Minor complications were pain and pleural effusion. During and after RFA, these complication usually showed but were self-limited. But during and after PCT, these complication never showed. Major complications after RFA or PTC are summarized in Table 2.